See the experiments, methods, and limitations behind existing claims before planning your next study.Know what the science actually supports before you trust the answer.
Press Enter β΅ to plan experiment
Explore by Goal
"The biology of mind bridges the sciences - concerned with the natural world - and the humanities - concerned with the meaning of human experience."
Key experimental levers: antigen selection (conserved NP/M2 vs HA head), delivery platform (DNA/mRNA, adenoviral or rare Ad vectors, LAIV, vectored platforms such as rabies or VSV replicons), route (intranasal mucosal vs intramuscular systemic), and antigen match/multivalency to address antigenic drift β each strongly affects breadth, mucosal immunity, durability and safety and strain-match considerations for HA-dominant vaccines .
Visualize first β core experimental variables and evidence-backed expected outcomes. Below: concise Plotly figures built from the extracted raw-study values in the provided dataset, then experimental design panels (what to test, readouts, controls, caveats).
Data shown: survival and peak weight loss after H5N1 challenge for animals primed with NP+M2 DNA and boosted with recombinant adenovirus intramuscular (i.m.), intranasal (i.n.), or cold-adapted (ca) intranasal. i.n. rAd produced the lowest weight loss while both rAd routes gave 100% survival; ca boost had lower durability and higher weight loss
Takeaway: a single saRNA-like platform (RESPONS AI H5) produced robust, persistent anti-H5 humoral responses detectable to day 252 with strong seroneutralisationβfield safety acceptable in 50 wild penguin chicksβthough no live-virus challenge was performed to measure efficacy
Interpretation: HI titers measured against the challenge antigen are positively predictive of survival and reduced shedding in SPF chickens, but antigenic drift can decouple vaccine-antigen HI titers from protection against drifted field virusesβthus strain matching or multivalent approaches are essential for HA-focused vaccines
Antigen arms: conserved internal (NP+M2) versus HA (clade-matched) versus multivalent HA (2 clades) β test separately and combined (NP+M2 + HA multivalent) to measure breadth
Platform arms: DNA (EP), mRNA-LNP, adenoviral vector (rare serotype, fully-deleted Ad), replicon/VSV or rabies vectored, and LAIV (dNS1 or cold-adapted) β prioritize platforms with human-use precedents and distinct immunological fingerprints (strong mucosal vs systemic vs T-cell bias)
Routes: compare i.m., i.n. (mucosal), and heterologous prime-boost (i.m. prime + i.n. boost) since mucosal boosting amplifies lung IgA and tissue-resident T cells tied to protection (see Vaccine 2009 & rabies-vectored mouse data)
Challenge panel: include at least two heterologous H5N1 clades (e.g., clade 1 and 2.3.4.4b or local circulating strains) and a drifted variant to measure cross-clade efficacy and the effect of antigenic distance on HI correlation
Readouts (ordered priority): survival and weight loss, lung viral titers (TCID50/EID50), mucosal IgA (BAL, nasal wash), serum VNAs and HI titers against challenge antigen, T-cell ELISPOT + lung-resident memory phenotyping, shedding (oropharyngeal/cloacal), histopathology. Correlate HI against challenge antigen with outcome to test predictive thresholds (as in J Virol 2015)
Important blindspots & biases to control for
Animal-model limits: mice/ferret/chicken results do not fully predict human immunity β include multiple species where feasible and interpret with caution
Antigenic drift: HA-focused vaccines require up-to-date seed matching or multivalent strategies; HI titers should be measured against the challenge antigen to be predictive
Durability: some platforms (rAd, DNA-LNP) show durable protection in preclinical models; cold-adapted responses may wane β plan long-term follow-up arms (months)
Safety and inflammation trade-offs: LAIV strategies (e.g., NS1 deletion vs cold-adapted) can differ in inflammatory profile and speed of T-cell induction; include safety signs, weight, histopathology, and inflammatory cytokine readouts
Primary sources used (inline evidence for every claim)
Confidence & what would change conclusions: Evidence-based confidence is moderate for the recommendation matrix (preclinical convergence across multiple platforms). Key disconfirming data would be reproducible failure of conserved-antigen strategies to protect across species or demonstration that HI titers against challenge antigen do not predict protection in multiple independent field trials; large human immunogenicity failures would force re-evaluation.
Preparing antigenic-distance matrices and plotting HI-titer protection thresholds using HA1 amino-acid sequences from provided studies to guide seed selection and multivalent design.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Universal protection from NP/M2 alone providing sterilizing immunity β falsified: NP/M2-focused strategies reduce disease and improve survival but generally do not prevent upper-respiratory shedding or fully sterilize infection, so HA-neutralizing antibodies remain required for sterilizing protection.
HI titer against vaccine antigen is always predictive β falsified: when drifted challenge antigens differ, HI against vaccine antigen poorly predicts protection; HI must be measured against challenge antigens to be predictive.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
Keep Exploring
